# A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

> **NCT05572463** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.**

## Conditions studied

- Unresectable Cutaneous Melanoma
- Metastatic Cutaneous Melanoma

## Interventions

- **COMBINATION_PRODUCT:** Sintilimab + IBI110

## Key facts

- **NCT ID:** NCT05572463
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-11-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor Strategy
- **Last updated:** 2022-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05572463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05572463, "A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05572463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*